{"transactions":[{"id":4155939,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":162630,"kind":"organization","name":"NeoMed Innovation V L.P.","position":1,"cik":"0001721884","reported_name":"NeoMed Innovation V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171724,"kind":"organization","name":"NeoMed Management (Jersey) Ltd","position":2,"cik":"0001722665","reported_name":"NeoMed Management (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162629,"kind":"organization","name":"NeoMed Innovation V Ltd","position":3,"cik":"0001722666","reported_name":"NeoMed Innovation V Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2017-11-20T23:15:22.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":952497,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The reported securities are held of record by NeoMed Innovation V L.P. NeoMed Management (Jersey) Limited is the Investment Manager to NeoMed Innovation V L.P. NeoMed Innovation V Limited is the general partner of Neomed Innovation V L.P. By virtue of such relationships, NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited may be deemed to have voting and investment power with respect to the shares held by NeoMed Innovation V L.P. Each of NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited disclaims beneficial ownership of the shares held by NeoMed Innovation V L.P., except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":279079},"source":{"system":"sec-edgar","filing":"0000899243-17-027028","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000089924317027028/doc4.xml","form_type":"4"}},{"id":4155938,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":162630,"kind":"organization","name":"NeoMed Innovation V L.P.","position":1,"cik":"0001721884","reported_name":"NeoMed Innovation V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171724,"kind":"organization","name":"NeoMed Management (Jersey) Ltd","position":2,"cik":"0001722665","reported_name":"NeoMed Management (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162629,"kind":"organization","name":"NeoMed Innovation V Ltd","position":3,"cik":"0001722666","reported_name":"NeoMed Innovation V Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2017-11-20T23:15:22.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":84040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The reported securities are held of record by NeoMed Innovation V L.P. NeoMed Management (Jersey) Limited is the Investment Manager to NeoMed Innovation V L.P. NeoMed Innovation V Limited is the general partner of Neomed Innovation V L.P. By virtue of such relationships, NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited may be deemed to have voting and investment power with respect to the shares held by NeoMed Innovation V L.P. Each of NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited disclaims beneficial ownership of the shares held by NeoMed Innovation V L.P., except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":41878},"source":{"system":"sec-edgar","filing":"0000899243-17-027028","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000089924317027028/doc4.xml","form_type":"4"}},{"id":4155937,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":162630,"kind":"organization","name":"NeoMed Innovation V L.P.","position":1,"cik":"0001721884","reported_name":"NeoMed Innovation V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171724,"kind":"organization","name":"NeoMed Management (Jersey) Ltd","position":2,"cik":"0001722665","reported_name":"NeoMed Management (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162629,"kind":"organization","name":"NeoMed Innovation V Ltd","position":3,"cik":"0001722666","reported_name":"NeoMed Innovation V Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2017-11-20T23:15:22.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":552487,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The reported securities are held of record by NeoMed Innovation V L.P. NeoMed Management (Jersey) Limited is the Investment Manager to NeoMed Innovation V L.P. NeoMed Innovation V Limited is the general partner of Neomed Innovation V L.P. By virtue of such relationships, NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited may be deemed to have voting and investment power with respect to the shares held by NeoMed Innovation V L.P. Each of NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited disclaims beneficial ownership of the shares held by NeoMed Innovation V L.P., except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":246682},"source":{"system":"sec-edgar","filing":"0000899243-17-027028","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000089924317027028/doc4.xml","form_type":"4"}},{"id":4155936,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":162630,"kind":"organization","name":"NeoMed Innovation V L.P.","position":1,"cik":"0001721884","reported_name":"NeoMed Innovation V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171724,"kind":"organization","name":"NeoMed Management (Jersey) Ltd","position":2,"cik":"0001722665","reported_name":"NeoMed Management (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162629,"kind":"organization","name":"NeoMed Innovation V Ltd","position":3,"cik":"0001722666","reported_name":"NeoMed Innovation V Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T23:15:22.000Z","date":"2017-11-20","kind":"purchase","acquired":true,"shares":300000,"price":10,"value":3000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The reported securities are held of record by NeoMed Innovation V L.P. NeoMed Management (Jersey) Limited is the Investment Manager to NeoMed Innovation V L.P. NeoMed Innovation V Limited is the general partner of Neomed Innovation V L.P. By virtue of such relationships, NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited may be deemed to have voting and investment power with respect to the shares held by NeoMed Innovation V L.P. Each of NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited disclaims beneficial ownership of the shares held by NeoMed Innovation V L.P., except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":867639,"source":{"system":"sec-edgar","filing":"0000899243-17-027028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000089924317027028/doc4.xml","form_type":"4"}},{"id":4155935,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":162630,"kind":"organization","name":"NeoMed Innovation V L.P.","position":1,"cik":"0001721884","reported_name":"NeoMed Innovation V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171724,"kind":"organization","name":"NeoMed Management (Jersey) Ltd","position":2,"cik":"0001722665","reported_name":"NeoMed Management (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162629,"kind":"organization","name":"NeoMed Innovation V Ltd","position":3,"cik":"0001722666","reported_name":"NeoMed Innovation V Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T23:15:22.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":279079,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The reported securities are held of record by NeoMed Innovation V L.P. NeoMed Management (Jersey) Limited is the Investment Manager to NeoMed Innovation V L.P. NeoMed Innovation V Limited is the general partner of Neomed Innovation V L.P. By virtue of such relationships, NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited may be deemed to have voting and investment power with respect to the shares held by NeoMed Innovation V L.P. Each of NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited disclaims beneficial ownership of the shares held by NeoMed Innovation V L.P., except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":567639,"source":{"system":"sec-edgar","filing":"0000899243-17-027028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000089924317027028/doc4.xml","form_type":"4"}},{"id":4155934,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":162630,"kind":"organization","name":"NeoMed Innovation V L.P.","position":1,"cik":"0001721884","reported_name":"NeoMed Innovation V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171724,"kind":"organization","name":"NeoMed Management (Jersey) Ltd","position":2,"cik":"0001722665","reported_name":"NeoMed Management (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162629,"kind":"organization","name":"NeoMed Innovation V Ltd","position":3,"cik":"0001722666","reported_name":"NeoMed Innovation V Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T23:15:22.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":41878,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The reported securities are held of record by NeoMed Innovation V L.P. NeoMed Management (Jersey) Limited is the Investment Manager to NeoMed Innovation V L.P. NeoMed Innovation V Limited is the general partner of Neomed Innovation V L.P. By virtue of such relationships, NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited may be deemed to have voting and investment power with respect to the shares held by NeoMed Innovation V L.P. Each of NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited disclaims beneficial ownership of the shares held by NeoMed Innovation V L.P., except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":288560,"source":{"system":"sec-edgar","filing":"0000899243-17-027028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000089924317027028/doc4.xml","form_type":"4"}},{"id":4155933,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":162630,"kind":"organization","name":"NeoMed Innovation V L.P.","position":1,"cik":"0001721884","reported_name":"NeoMed Innovation V L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":171724,"kind":"organization","name":"NeoMed Management (Jersey) Ltd","position":2,"cik":"0001722665","reported_name":"NeoMed Management (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":162629,"kind":"organization","name":"NeoMed Innovation V Ltd","position":3,"cik":"0001722666","reported_name":"NeoMed Innovation V Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T23:15:22.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":246682,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"The reported securities are held of record by NeoMed Innovation V L.P. NeoMed Management (Jersey) Limited is the Investment Manager to NeoMed Innovation V L.P. NeoMed Innovation V Limited is the general partner of Neomed Innovation V L.P. By virtue of such relationships, NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited may be deemed to have voting and investment power with respect to the shares held by NeoMed Innovation V L.P. Each of NeoMed Management (Jersey) Limited and NeoMed Innovation V Limited disclaims beneficial ownership of the shares held by NeoMed Innovation V L.P., except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":246682,"source":{"system":"sec-edgar","filing":"0000899243-17-027028","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000089924317027028/doc4.xml","form_type":"4"}}]}